In IMT, ALK gene rearrangements or fusions occur in approximately 50%-70% of cases (5), with common fusion partners including TPM3, TPM4, SEC31A, TFG, RANBP2, CLTC, FN1, LMNA, and PRKAR1A (16, 18). This evidence concerns the gene PRKAR1A and inflammatory myofibroblastic tumor.